


-43-

5 WE CLAIM:

1. A compound of the formula:




10

Formula I

wherein R^1 is hydrogen or (C_1-C_6) alkyl;

15 R^2 is selected from the group consisting of:



R^3 is (C_1-C_6) alkyl, or $(CH_2)_nX$;

20

R^4 is (C_1-C_6) alkyl, or $(CH_2)_nX$;

R^5 is hydrogen, (C_1-C_6) alkyl, or $(CH_2)_nX$;

25 X is selected from the group consisting of a halogen, NR^aR^b ,

N-morpholino, N-piperidine, N-pyrrolidine, or N-azepane;

n is an integer from 1-4;

m is an integer from 1-3;


-44-

- 5 R^a and R^b are each independently hydrogen or (C_1-C_6) alkyl;
and the pharmaceutically acceptable salts thereof.

2. A compound according to Claim 1 wherein:

R^1 is hydrogen or (C_1-C_6) alkyl;

10 R^2 is



R^3 is (C_1-C_6) alkyl, or $(CH_2)_nX$;

X is selected from the group consisting of a halogen, NR^aR^b ,

N -morpholino, N -piperidine, N -pyrrolidine, or N -azepane;

15 n is an integer from 1-4;

m is an integer from 1-3;


R^a and R^b are each independently hydrogen or (C_1-C_6) alkyl;

and the pharmaceutically acceptable salts thereof.

20 3. A compound according to Claim 1 wherein:

R^1 is hydrogen or (C_1-C_6) alkyl;

R^2 is



R^4 is (C_1-C_6) alkyl, or $(CH_2)_nX$;

25 X is selected from the group consisting of a halogen, NR^aR^b ,

N -morpholino, N -piperidine, N -pyrrolidine, or N -azepane;

n is an integer from 1-4;

-45-

5 m is an integer from 1-3;


R^a and R^b are each independently hydrogen or (C₁-C₆)alkyl;

and the pharmaceutically acceptable salts thereof.

4. A compound according to Claim 1 wherein:

10 R^1 is hydrogen or (C₁-C₆) alkyl;

R^2 is



R^5 is hydrogen, (C₁-C₆)alkyl, or (CH₂)_nX;

X is selected from the group consisting of a halogen, NR^aR^b ,

15 N-morpholino, N-piperidine, N-pyrrolidine, or N-azepane;

n is an integer from 1-4;

m is an integer from 1-3;

R^a and R^b are each independently hydrogen or (C₁-C₆)alkyl;

and the pharmaceutically acceptable salts thereof.

20

5. A compound according to Claims 1-4 wherein m is 1.

6. A compound according to Claims 1-5 wherein R^3 is methyl.

25

7. A compound according to Claims 1-6 wherein R^1 is methyl.

8. A pharmaceutical formulation comprising a compound according to any one of Claims 1 to 7 in combination with a pharmaceutically acceptable diluent, excipient or carrier.

30

-46-

5 9. A method of treating susceptible neoplasms in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound according to any one of Claims 1 to 7.

10 10. A method of treating fibrosis in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound according to any one of Claims 1-7.